# Clinical Study of Recombinant Mycobacterium Tuberculosis ESAT6-CFP10 Allergen

> **NCT02623556** · PHASE3 · COMPLETED · sponsor: **Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd.** · enrollment: 1090 (estimated)

## Conditions studied

- Tuberculosis

## Interventions

- **BIOLOGICAL:** ESAT6-CFP10 (10ug/ml) in left arm and TB-PPD in right arm
- **BIOLOGICAL:** ESAT6-CFP10 (10ug/ml) in right arm and TB-PPD in left arm

## Key facts

- **NCT ID:** NCT02623556
- **Lead sponsor:** Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-12
- **Primary completion:** 2018-03
- **Final completion:** 2018-03
- **Target enrollment:** 1090 (ESTIMATED)
- **Last updated:** 2018-04-12

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02623556

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02623556, "Clinical Study of Recombinant Mycobacterium Tuberculosis ESAT6-CFP10 Allergen". Retrieved via AI Analytics 2026-06-16 from https://api.ai-analytics.org/clinical/NCT02623556. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*